{"id":"NCT02695719","sponsor":"Takeda","briefTitle":"Lubiprostone for Treatment of Chronic Idiopathic Constipation","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-14","primaryCompletion":"2017-01-20","completion":"2017-02-24","firstPosted":"2016-03-01","resultsPosted":"2018-12-31","lastUpdate":"2018-12-31"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lubiprostone","otherNames":["AMITIZA"]}],"arms":[{"label":"Lubiprostone 24 μg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.","primaryOutcome":{"measure":"Spontaneous Bowel Movement (SBM) Frequency at Week 1","timeFrame":"Week 1","effectByArm":[{"arm":"Placebo","deltaMin":3.1,"sd":1.75},{"arm":"Lubiprostone 24 μg","deltaMin":4.4,"sd":2.65}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":["Nausea","Dyspepsia","Diarrhoea","Headache"]}}